Presidio Medical, Inc
Clinical-stage medical device company developing an ultra low frequency neuromodulation platform to treat diseases of undesired neural activity, with an initial indication for chronic nociceptive pain. Activities include preclinical research, human clinical trials, device engineering, and regulatory submissions.
Industries
N/A
Nr. of Employees
small (1-50)
Presidio Medical, Inc
San Mateo / South San Francisco, CA (headquarters listed in company materials)
Patents
Products
Implantable ultra low frequency neuromodulation system (developmental)
An implantable spinal neuromodulation system delivering ultra low frequency waveforms via epidural leads intended to reduce neuronal signaling associated with nociceptive pain; currently in clinical development.
Implantable ultra low frequency neuromodulation system (developmental)
An implantable spinal neuromodulation system delivering ultra low frequency waveforms via epidural leads intended to reduce neuronal signaling associated with nociceptive pain; currently in clinical development.
Services
Design and conduct of preclinical studies and human clinical trials, including first-in-human studies and pivotal randomized controlled trials for implantable neuromodulation therapies.
Design and conduct of preclinical studies and human clinical trials, including first-in-human studies and pivotal randomized controlled trials for implantable neuromodulation therapies.
Expertise Areas
- Neuromodulation research and development
- Chronic pain clinical research
- Implantable medical device engineering
- Translational neuroscience and mechanism-of-action studies
Key Technologies
- Ultra low frequency neuromodulation
- Spinal cord stimulation via epidural leads
- Computational neural modeling
- Electrochemistry for device interfaces
News & Updates
FDA granted an Investigational Device Exemption enabling a global pivotal randomized controlled trial in the United States and Australia; announcement also notes CFO appointment.
Closed a $72M Series C financing to expand team, scale manufacturing, and conduct long-term pivotal clinical studies.
Peer-reviewed publication describing preclinical, computational, and clinical evidence that ultra low frequency waveforms can reversibly block axonal conduction and reduce chronic pain.
Announced $30M financing to develop technology and expand platform applications.
Publication describing inhibition of sensory signaling to the thalamus and effects on thalamic neuron firing in a model of neuropathic pain.
Publication demonstrating mechanism-of-action and clinical efficacy signals across preclinical and early human studies.
FDA granted an Investigational Device Exemption enabling a global pivotal randomized controlled trial in the United States and Australia; announcement also notes CFO appointment.
Closed a $72M Series C financing to expand team, scale manufacturing, and conduct long-term pivotal clinical studies.
Peer-reviewed publication describing preclinical, computational, and clinical evidence that ultra low frequency waveforms can reversibly block axonal conduction and reduce chronic pain.
Announced $30M financing to develop technology and expand platform applications.
Publication describing inhibition of sensory signaling to the thalamus and effects on thalamic neuron firing in a model of neuropathic pain.
Publication demonstrating mechanism-of-action and clinical efficacy signals across preclinical and early human studies.